Engineering Glucose Responsiveness Into Insulin
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Insulin has a narrow therapeutic index, reflected in a small margin between a dose that achieves good glycemic control and one that causes hypoglycemia. Once injected, the clearance of exogenous insulin is invariant regardless of blood glucose, aggravating the potential to cause hypoglycemia. We sought to create a “smart” insulin, one that can alter insulin clearance and hence insulin action in response to blood glucose, mitigating risk for hypoglycemia. The approach added saccharide units to insulin to create insulin analogs with affinity for both the insulin receptor (IR) and mannose receptor C-type 1 (MR), which functions to clear endogenous mannosylated proteins, a principle used to endow insulin analogs with glucose responsivity. Iteration of these efforts culminated in the discovery of MK-2640, and its in vitro and in vivo preclinical properties are detailed in this report. In glucose clamp experiments conducted in healthy dogs, as plasma glucose was lowered stepwise from 280 mg/dL to 80 mg/dL, progressively more MK-2640 was cleared via MR, reducing by ∼30% its availability for binding to the IR. In dose escalations studies in diabetic minipigs, a higher therapeutic index for MK-2640 (threefold) was observed versus regular insulin (1.3-fold).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“Introduction Nearly a century has passed since the discovery of insulin yet the remarkable success of insulin therapy has been tempered by the risk of iatrogenic hypoglycemia, which stands as a major barrier to achievement of tight glycemic control [1-4].”
BackgroundRisk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825 · cited 2×
“Insulin-induced hypoglycemia is the most serious acute complication of using this medicine [2, 3].”
BackgroundHypoglycemia in the Diabetes Control and Complications Trial
The Diabetes Control and Complications Trial Research Group (1997) · Diabetes · doi:10.2337/diab.46.2.271 · Cited by 746 · cited 2×
“Insulin-induced hypoglycemia is the most serious acute complication of using this medicine [2, 3].”
Background
Cited by
Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs
Yu, J., Wang, J., Zhang, Y., Chen, G., Mao, W., Ye, Y., Kahkoska, A. R., Buse, J. B., Langer, R., & Gu, Z. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0508-y · Cited by 604
Glucose‐Responsive Insulin and Delivery Systems: Innovation and Translation
Wang, J., Wang, Z., Yu, J., Kahkoska, A. R., Buse, J. B., & Gu, Z. (2020) · Advanced Materials · doi:10.1002/adma.201902004 · Cited by 295
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Glucose-sensitive insulin with attenuation of hypoglycaemia
Hoeg-Jensen, T., Kruse, T., Brand, C. L., Sturis, J., Fledelius, C., Nielsen, P. K., Nishimura, E., Madsen, A. R., Lykke, L., Halskov, K. S., et al. (2024) · Nature · doi:10.1038/s41586-024-08042-3 · Cited by 65
“This protocol was inspired by the use of α-methyl-d-mannopyranose to trigger glucose-sensitive insulin derivatives that rely on the previously described mannose receptor principle 12 .”
Wang, J., Wang, Z., Yu, J., Zhang, Y., Zeng, Y., & Gu, Z. (2019) · Biomaterials Science · doi:10.1039/c9bm01283d · Cited by 21
Metadata
- Authors
- Kaarsholm, N. C., Lin, S., Yan, L., Kelly, T., van Heek, M., Mu, J., Wu, M., Dai, G., Cui, Y., Zhu, Y., Carballo-Jane, E., Reddy, V., Zafian, P., Huo, P., Shi, S., Antochshuk, V., Ogawa, A., Liu, F., Souza, S. C., Seghezzi, W., Duffy, J. L., Erion, M., Nargund, R. P., & Kelley, D. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-11-02
- Volume
- 67
- Issue
- 2
- Pages
- 299-308
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2767167538
- Cited by
- 91
- References
- 3
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.